Should I buy or sell HUTCHMED stock right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for HUTCHMED in the last twelve months. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" HCM shares. View HCM analyst ratings or view top-rated stocks .

What is HUTCHMED's stock price target for 2024?

4 Wall Street analysts have issued 12-month price objectives for HUTCHMED's shares. Their HCM share price targets range from $17.00 to $50.00. On average, they anticipate the company's share price to reach $29.70 in the next twelve months. This suggests a possible upside of 80.2% from the stock's current price. View analysts price targets for HCM or view top-rated stocks among Wall Street analysts .

How have HCM shares performed in 2024?

HUTCHMED's stock was trading at $18.11 at the beginning of the year. Since then, HCM shares have decreased by 9.0% and is now trading at $16.48. View the best growth stocks for 2024 here .

When is HUTCHMED's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 22nd 2024. View our HCM earnings forecast .

What ETFs hold HUTCHMED's stock?

ETFs with the largest weight of HUTCHMED (NASDAQ:HCM) stock in their portfolio include Range Cancer Therapeutics ETF (CNCR) . Loncar China Biopharma ETF (CHNA) .

What other stocks do shareholders of HUTCHMED own?

Based on aggregate information from My MarketBeat watchlists, some companies that other HUTCHMED investors own include Telford Homes (TEF) , AbbVie (ABBV) , Exelixis (EXEL) , GW Pharmaceuticals (GWPH) , Premier Oil (PMO) , CRISPR Therapeutics (CRSP) , AT&T (T) , Johnson & Johnson (JNJ) , NVIDIA (NVDA) and Weyerhaeuser (WY) .

When did HUTCHMED IPO?

HUTCHMED (HCM) raised $100 million in an initial public offering on Thursday, March 17th 2016. The company issued 6,100,000 shares at a price of $16.33 per share. BofA Merrill Lynch and Deutsche Bank Securities served as the underwriters for the IPO and Stifel, Canaccord Genuity, Panmure Gordon and CITIC CLSA were co-managers.

Who are HUTCHMED's major shareholders?

HUTCHMED's stock is owned by a variety of institutional and retail investors. Top institutional investors include Hennion & Walsh Asset Management Inc. (0.03%).

How do I buy shares of HUTCHMED?

Shares of HCM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:HCM

HUTCHMED (HCM) Stock Price, News & Analysis

→ Did you know you can now trade Bitcoin in your regular brokerage account? (From DTI) (Ad)

Free HCM Stock Alerts

$16.48

+0.12 (+0.73%)

(As of 03:15 PM ET)

Compare

Today's Range: $16.21
▼
$16.53
50-Day Range: $13.53
▼
$18.56
52-Week Range: $10.68
▼
$20.73

Volume: 32,750 shs
Average Volume: 122,569 shs
Market Capitalization: $2.87 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $29.70

Get HUTCHMED alerts:

HUTCHMED MarketRank™ Stock Analysis

Analyst Rating: Moderate Buy
2.75 Rating Score
Upside/Downside: 80.2% Upside
$29.70 Price Target
Short Interest: Bearish
0.29% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.91
Based on 2 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($0.45) to $0.48 Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.49 out of 5 stars

Medical Sector

707th out of 918 stocks

Pharmaceutical Preparations Industry

314th out of 417 stocks

3.4

Analyst's Opinion

Consensus Rating
HUTCHMED has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.
Amount of Analyst Coverage
HUTCHMED has received no research coverage in the past 90 days.

2.0

Short Interest

Percentage of Shares Shorted
0.29% of the outstanding shares of HUTCHMED have been sold short.
Short Interest Ratio / Days to Cover
HUTCHMED has a short interest ratio ("days to cover") of 4.
Change versus previous month
Short interest in HUTCHMED has recently increased by 3.38%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
HUTCHMED does not currently pay a dividend.
Dividend Growth
HUTCHMED does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for HCM.

3.3

News and Social Media Coverage

News Sentiment
HUTCHMED has a news sentiment score of 0.91. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.52 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 2 news articles for HUTCHMED this week, compared to 1 article on an average week.
MarketBeat Follows
2 people have added HUTCHMED to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, HUTCHMED insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 3.60% of the stock of HUTCHMED is held by insiders.
Percentage Held by Institutions
Only 8.82% of the stock of HUTCHMED is held by institutions.

0.6

Earnings and Valuation

Earnings Growth
Earnings for HUTCHMED are expected to grow in the coming year, from ($0.45) to $0.48 per share.
Price to Book Value per Share Ratio
HUTCHMED has a P/B Ratio of 3.86. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Insiders Exposed

The Hard Truth About Investing For Retirement

Here’s the cold, hard truth about investing: The more capital you have, the more risk averse you can afford to be. But when you’re staring down the barrel of retirement and you’ve only got 5, 10, 50 or $100,000 saved, you’ve got to be more aggressive. In an exclusive online training, the Market expert Steven Place is revealing a powerful “roadmap” that’s leading everyday investors to easy, triple-digit wins, even if they don’t have a lot of experience in trading.

Click To Access This Powerful Training Right Now!

About HUTCHMED Stock (NASDAQ:HCM)

HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in Hong Kong and internationally. The company develops Savolitinib for the treatment of non-small cell lung cancer (NSCLC), papillary renal cell carcinoma (RCC), and gastric cancer (GC); and Fruquintinib, an inhibitor for colorectal cancer (CRC), breast cancer, gastric cancer, microsatellite stable-CRC endometrial cancer (EMC), NSCLC, RCC, gastrointestinal, cervical, and solid tumors. It also develops Surufatinib, which is used for the treatment of pancreatic neuroendocrine tumor (NET), non-pancreatic NET, neuroendocrine carcinoma, SCLC, biliary tract cancer, and solid tumors; and Sovleplenib that treats hematological cancers and certain chronic immune diseases. In addition, it develops Tazemetostat for the treatment of certain epithelioid sarcoma and follicular lymphoma patients; HMPL-306, an inhibitor for hematological malignancies, gliomas, chondrosarcomas, cholangiocarcinomas, and solid tumors; HMPL-760, a Bruton's tyrosine kinase inhibitor; HMPL-453 for intrahepatic cholangiocarcinoma and solid tumors; HMPL-295 and HMPL-415 for solid tumors; HMPL-653 for metastatic solid tumors and tenosynovial giant cell tumors; and HMPL-A83 for the treatment of malignant neoplasms. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, Takeda, BeiGene Ltd., Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., Genor Biopharma Co. Ltd., Shanghai Junshi Biosciences Co. Ltd., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. HUTCHMED (China) Limited was incorporated in 2000 and is headquartered in Hong Kong, Hong Kong.

HCM Stock Price History

30 days | 90 days | 365 days | Advanced Chart

HCM Stock News Headlines

April 11, 2024 | americanbankingnews.com

HUTCHMED (NASDAQ:HCM) Shares Gap Up to $16.87

April 5, 2024 | finance.yahoo.com

HUTCHMED Highlights Data to be Presented at AACR Congress 2024

April 19, 2024 | DTI (Ad)

Did you know you can now trade Bitcoin in your regular brokerage account?

You see, thanks to one unique investor's brand new discovery - anyone with a regular brokerage account can now tap into the most explosive asset in history! That means you can skip the hassle of opening a Coinbase account… Bypass the fees and hard-to-remember passwords… Heck, you don’t even need a crypto wallet!

April 5, 2024 | globenewswire.com

HUTCHMED Highlights Data to be Presented at AACR Congress 2024

April 2, 2024 | markets.businessinsider.com

HUTCHMED (China) And Innovent's Endometrial Cancer Treatment Granted Priority Review By NMPA

April 2, 2024 | globenewswire.com

HUTCHMED and Innovent Jointly Announce NDA Acceptance in China for Fruquintinib Combination with Sintilimab for the Treatment of Advanced Endometrial Cancer with Priority Review Status

March 28, 2024 | finance.yahoo.com

Do Its Financials Have Any Role To Play In Driving HUTCHMED (China) Limited's (LON:HCM) Stock Up Recently?

March 27, 2024 | globenewswire.com

HUTCHMED Announces Savolitinib sNDA Accepted in China for Treatment-Naïve or Previously Treated Patients with Locally Advanced or Metastatic MET Exon 14 NSCLC

April 19, 2024 | DTI (Ad)

Did you know you can now trade Bitcoin in your regular brokerage account?

March 21, 2024 | globenewswire.com

HUTCHMED Initiates Registration Stage of the ESLIM-02 Phase II/III Trial of Sovleplenib for Warm Antibody Autoimmune Hemolytic Anemia in China

March 20, 2024 | seekingalpha.com

Hutchmed Is Turning Profitable

March 14, 2024 | msn.com

Affimed N.V., Hutchmed, Annexon among healthcare movers

March 1, 2024 | seekingalpha.com

HUTCHMED (China) Limited (HCM) Q4 2023 Earnings Call Transcript

March 1, 2024 | finance.yahoo.com

HUTCHMED (China) Full Year 2023 Earnings: EPS: US$0.12 (vs US$0.43 loss in FY 2022)

February 28, 2024 | globenewswire.com

HUTCHMED Reports 2023 Full Year Results and Provides Business Updates

February 17, 2024 | finance.yahoo.com

HCM Mar 2024 17.500 call

February 6, 2024 | finance.yahoo.com

HUTCHMED Highlights Presentation of Phase III Data on Fruquintinib in Second-Line Gastric Cancer at ASCO Plenary Series Session

February 2, 2024 | finanznachrichten.de

HUTCHMED (China) Limited: HUTCHMED Announces that Inmagene Exercises Option to License Two Drug Candidates as Part of Strategic Partnership

February 2, 2024 | finance.yahoo.com

Inmagene Exercises Option to Obtain Exclusive Worldwide License for IMG-007 and IMG-004 from HUTCHMED

January 30, 2024 | finance.yahoo.com

HUTCHMED Receives ELUNATE® (fruquintinib) Marketing Approval in Hong Kong for Treatment of Metastatic Colorectal Cancer

January 11, 2024 | msn.com

Chinese regulators accept HUTCHMED application for solveplenib

January 10, 2024 | finance.yahoo.com

HUTCHMED Announces NDA Acceptance in China for Sovleplenib for the Treatment of Primary Immune Thrombocytopenia with Priority Review Status

December 24, 2023 | ca.finance.yahoo.com

HUTCHMED (China) Limited (0013.HK)

December 13, 2023 | finance.yahoo.com

HUTCHMED Announces Continued Inclusion of ELUNATE® (fruquintinib) and SULANDA® (surufatinib) in the National Reimbursement Drug List in China at Current Terms

December 12, 2023 | finance.yahoo.com

HUTCHMED Announces that it has Completed Enrollment of a Phase II/III Trial of Fruquintinib in Combination with Sintilimab for Advanced Renal Cell Carcinoma in China

December 1, 2023 | finanznachrichten.de

HUTCHMED (China) Limited: HUTCHMED Highlights Clinical Data to be Presented at 2023 ESMO Asia and ESMO Immuno-Oncology Congresses

December 1, 2023 | seekingalpha.com

HUTCHMED Deserves An Upgrade After U.S. FDA Approval Of Cancer Drug

See More Headlines

Receive HCM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for HUTCHMED and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today: 4/19/2024
Next Earnings (Estimated): 5/22/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:HCM
CUSIP: N/A
CIK: 1648257
Web: www.chi-med.com
Phone: 852-2121-3888
Fax: 852-2128-1778
Employees: 1,988
Year Founded: 2000

Price Target and Rating

Average Stock Price Target: $29.70
High Stock Price Target: $50.00
Low Stock Price Target: $17.00
Potential Upside/Downside: +81.5%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.75
Research Coverage: 4 Analysts

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: 0.06
Current Ratio: 2.72
Quick Ratio: 2.60

Sales & Book Value

Annual Sales: $838 million
Price / Sales: 3.40
Cash Flow: $0.62 per share
Price / Cash Flow: 26.30
Book Value: $4.27 per share
Price / Book: 3.83

Miscellaneous

Outstanding Shares: 174,250,000
Free Float: 167,978,000
Market Cap: $2.85 billion
Optionable: Not Optionable
Beta: 0.81

Social Links

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google

Growth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.

Get This Free Report

Key Executives

Mr. Chi Keung To ACGI (Age 73)
B.Sc., M.B.A., Executive Chairman
Comp: $85k
Dr. Wei-Guo Su B.Sc. (Age 65)
Ph.D., CEO, Chief Scientific Officer & Executive Director
Comp: $2.45M
Mr. Chig Fung Cheng BEc (Age 57)
CA, CFO & Executive Director
Comp: $962.15k
Ms. Edith Shih BSE (Age 72)
C.S., CGP, EdM, FCIS, FCS, FCS(PE), M.A., P.E, Company Secretary & Non-Executive Director
Dr. Karen Jane Atkin (Age 58)
Executive VP & COO
David Ng
Head of Investor Relations & Capital Strategies
Mr. Charles George Rupert Nixon (Age 54)
Group General Counsel
Mr. Kin Hung Lee M.B.A. (Age 47)
Senior Vice President of Corporate Management & Communications
Ms. Selina Zhang
Senior Vice President of Global Human Resources
Dr. Qingmei Wang Ph.D. (Age 61)
Senior Vice President of Business Development & Strategic Alliances

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

HCM Stock Analysis - Frequently Asked Questions

Should I buy or sell HUTCHMED stock right now?: 4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for HUTCHMED in the last twelve months. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" HCM shares.
View HCM analyst ratings or view top-rated stocks.
What is HUTCHMED's stock price target for 2024?: 4 Wall Street analysts have issued 12-month price objectives for HUTCHMED's shares. Their HCM share price targets range from $17.00 to $50.00. On average, they anticipate the company's share price to reach $29.70 in the next twelve months. This suggests a possible upside of 80.2% from the stock's current price.
View analysts price targets for HCM or view top-rated stocks among Wall Street analysts.
How have HCM shares performed in 2024?: HUTCHMED's stock was trading at $18.11 at the beginning of the year. Since then, HCM shares have decreased by 9.0% and is now trading at $16.48.
View the best growth stocks for 2024 here.
When is HUTCHMED's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 22nd 2024.
View our HCM earnings forecast.
What ETFs hold HUTCHMED's stock?: ETFs with the largest weight of HUTCHMED (NASDAQ:HCM) stock in their portfolio include Range Cancer Therapeutics ETF (CNCR).Loncar China Biopharma ETF (CHNA).

What other stocks do shareholders of HUTCHMED own?: Based on aggregate information from My MarketBeat watchlists, some companies that other HUTCHMED investors own include Telford Homes (TEF), AbbVie (ABBV), Exelixis (EXEL), GW Pharmaceuticals (GWPH), Premier Oil (PMO), CRISPR Therapeutics (CRSP), AT&T (T), Johnson & Johnson (JNJ), NVIDIA (NVDA) and Weyerhaeuser (WY).
When did HUTCHMED IPO?: HUTCHMED (HCM) raised $100 million in an initial public offering on Thursday, March 17th 2016. The company issued 6,100,000 shares at a price of $16.33 per share. BofA Merrill Lynch and Deutsche Bank Securities served as the underwriters for the IPO and Stifel, Canaccord Genuity, Panmure Gordon and CITIC CLSA were co-managers.
Who are HUTCHMED's major shareholders?: HUTCHMED's stock is owned by a variety of institutional and retail investors. Top institutional investors include Hennion & Walsh Asset Management Inc. (0.03%).
How do I buy shares of HUTCHMED?: Shares of HCM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:HCM) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial